Recent Updates
Recently added Catalysts

VEC-162

Phase 3

Insomnia | Small molecule | Other |Vanda Pharmaceuticals Inc.|Last Updated: Oct 15, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment411
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00291187VEC-162 Study in Healthy Adult Volunteers in a Model of InsomniaPHASE3 COMPLETED 411Feb 1, 2006Aug 1, 2006Oct 15, 201419 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Average Improvement of Latency to Persistent Sleep (LPS)
Night 1

The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.

Secondary Endpoints
Average Improvement of Wake After Sleep Onset (WASO)
Night 1
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATORTake orally 30 minutes prior to bedtime.
20 mg VEC-162EXPERIMENTAL20 mg taken orally 30 minutes prior to bedtime.
50 mg VEC-162EXPERIMENTAL50 mg taken orally 30 minutes prior to bedtime.
100 mg VEC-162EXPERIMENTAL100 mg taken orally 30 minutes prior to bedtime.
Interventions
NameTypeDescription
20 mg VEC-162DRUG20 mg VEC-162
50 mg VEC-162DRUG50 mg VEC-162
100 mg VEC-162DRUG100 mg VEC-162
PlaceboDRUGPlacebo
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites19

Inclusion Criteria: * Healthy subjects with no medical, psychiatric or current sleep disorders. * Subject must sign a written consent form. Exclusion Criteria: * Recent history of night shift work or jet lag. * Prior experience sleeping in a sleep lab environment. * History of sleep disorders.

Countries:United States
Unlock Eligibility Criteria